TY - JOUR T1 - Immune responses to a single dose of the AZD1222/Covishield vaccine at 16 weeks in individuals in Sri Lanka JF - medRxiv DO - 10.1101/2021.07.26.21261122 SP - 2021.07.26.21261122 AU - Chandima Jeewandara AU - Dinuka Guruge AU - Pradeep Darshana Pushpakumara AU - Achala Kamaladasa AU - Inoka Sepali Aberathna AU - Shyrar Tanussiya AU - B Banuri Gunasekera AU - Ayesha Wijesinghe AU - Osanda Dissanayake AU - Heshan Kuruppu AU - Thushali Ranasinghe AU - Deshni Jayathilaka AU - Shashika Dayarathna AU - Dinithi Ekanayake AU - MPDJ Jayamali AU - Nayanathara Gamalath AU - Anushika Mudumkotuwa AU - Gayasha Somathilake AU - Madhushika Dissanayake AU - Michael Harvie AU - Thashmi Nimasha AU - Deshan Madusanka AU - Tibutius Jayadas AU - Ruwan Wijayamuni AU - Lisa Schimanski AU - Pramila Rijal AU - Tiong .K. Tan AU - Alain Townsend AU - Graham S. Ogg AU - Gathsaurie Neelika Malavige Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/28/2021.07.26.21261122.abstract N2 - Introduction Due to limited access to vaccines, many countries have only administered a single dose of the AZD1222, while the dosage intervals have increased ≥ weeks. We sought to investigate the immunogenicity of a single dose of vaccine at ≥ 16 weeks.Methods SARS-CoV-2 specific antibodies in 553 individuals and antibodies to the receptor binding domain (RBD) of the Wuhan virus (WT) and the variants of concern (VOCs), ACE2 receptor blocking antibodies, ex vivo and cultured IFNγ T cell responses and B cell ELISpot responses were investigated in a sub-cohort.Results The seropositivity rates in those >70 years of age (93.7%) was not significantly different compared to other age groups (97.7 to 98.2, Pearson Chi-Square = 7.8, p-value = 0.05). The antibody titres (antibody index) significantly declined (p<0.0001) with increase in age. 18/69 (26.1%) of individuals did not have ACE2 receptor blocking antibodies, while responses to the RBD of WT (p=0.03), B.1.1.7 (p=0.04) and B.1.617.2 (p=0.02) were significantly lower in those who were >60 years. Ex vivo IFN γ T cell ELISpot responses were seen in 10/66 (15.1%), while only a few expressed CD107a. However, >85% had a high frequency of cultured IFNγ T cell ELISpot responses and B cell ELISpots.Conclusion Virus specific antibodies were maintained at ≥ 16 weeks after receiving a single dose of AZD1222, although levels were lower to VOCs, especially in older individuals. A single dose induced a high frequency of memory T and B cell responses.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe are grateful to the World Health Organization, UK Medical Research Council and the Foreign and Commonwealth Office for support. T.K.T. is funded by the Townsend-Jeantet Prize Charitable Trust (charity number 1011770) and the EPA Cephalosporin Early Career Researcher Fund. A.T. are funded by the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China (grant no. 2018-I2M-2-002). We thank WBP, CBP, EGB and ANB for generous donations to the TJP Trust to support the production and distribution of HAT reagents.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was granted by the Ethics Review Committee of the University of Sri Jayewardenepura.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available within the manuscript, figures and the supplementary figures.All data is available within the manuscript, figures and the supplementary figures. ER -